Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma

BACKGROUND: Immunotherapy with immune checkpoint inhibitor (ICI) is a promising treatment for unresectable hepatocellular carcinoma (HCC). However, whether ICIs would have the risk of hepatitis B virus (HBV) reactivation and the necessary of nucleos(t)ide analogs (NUCs) prophylaxis are still unclear...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Lee, Pei-Chang, Chao, Yee, Chen, Ming-Huang, Lan, Keng-Hsin, Lee, I-Cheng, Hou, Ming-Chih, Huang, Yi-Hsiang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2020
Pynciau:
Clinical/Translational Cancer Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7462159/
https://ncbi.nlm.nih.gov/pubmed/32863270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001072
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg